Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Mining EMR’s Could Help Depression Patients Find the Right Treatment

By American College of Neuropsychopharmacology | December 8, 2017

Personalized medicine has been one of the most promising medical developments in recent years. To personalize treatment for patients, some doctors have turned to predictive models to help determine which patients will benefit from different treatments.

A new study from Massachusetts General Hospital and Harvard University finds that using data from electronic medical records in those models could hold a lot of promise.

Researchers MGH’s Roy Perlis and Harvard’s Finale Doshi-Velez, joined by postdoctoral researcher Michael Hughes, looked over large amounts of electronic medical record data from more than 50,000 people with depression, a condition that is notoriously difficult to treat. Patients often try several different treatments before arriving at an effective one.

The researchers applied machine learning to sort the data into depression subtypes, some of which weren’t necessarily standardized. The subtypes represented clusters of symptoms and features spotlighted by the data–such as age, sexual dysfunction, weight gain, or obesity.

Doshi-Velez’s team also looked at 16 types of antidepressants that were ultimately successful in treating the patients’ depression. From these data, they were able to develop an algorithm to predict an antidepressant’s effectiveness based on depression subtypes.

When implemented in clinical settings, the new tool was more accurate than existing methods, the researchers found. And clinicians polled by the researchers said they found the tool more user-friendly than existing predictive models.

As there is a 50 percent failure rate among patients trying a first treatment for depression, and a 50 percent failure rate among those who try a second type of treatment, cutting down on the guesswork involved could be life-changing. “Each try can take multiple weeks to assess, while you’re playing around with dosages. And these are already people for whom morale is sapped,” says Doshi-Velez. “Even if we could make a modest improvement — for instance, one less try–this could be a very significant result.”

While the researchers studied the impact of mining records on depression, their method could apply more broadly and help patients with various health problems, mental and physical.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE